Autoimmune responses in patients with linear IgA bullous dermatosis: both autoantibodies and T lymphocytes recognize the NC16A domain of the BP180 molecule.
Linear IgA bullous disease (LABD) is an autoimmune skin disease characterized by subepidermal blisters and IgA autoantibodies directed against the epidermal basement membrane zone (BMZ) of the skin. Various antigens have been identified as targets of IgA autoantibodies including BP180, a type II glycoprotein that spans the BMZ and lamina lucida. Previously, we have identified a subset of LABD patients whose sera contained IgA antibodies against the 16th noncollagenous (NC16A) domain of BP180. NC16A was previously shown to harbor epitopes that are recognized by both autoantibodies and T cells from patients with bullous pemphigoid and herpes gestationis and is thought to be associated with the development of these immunobullous diseases. The aim of this study was to determine whether T lymphocytes from LABD patients with anti-NC16A IgA autoantibodies respond to epitopes in the same region of the BP180 protein. Indeed, of the four LABD patients in our study, all had T cells that specifically proliferated in response to NC16A. Moreover, two subfragments of NC16A were identified as the predominant targets of LABD T cells. Further analysis of T cell lines and clones derived from these patients revealed that these cells express a CD4 memory T cell phenotype and secrete a Th1/Th2 mixed-cytokine profile, characteristics similar to those of T cells in bullous pemphigoid patients. Our data suggest that the BP180 protein, typically the NC16A region, is the common target of both cellular and humoral immune responses in some LABD patients. This information helps to further elucidate the autoimmune mechanisms in this disease.
Lin
Mong-Shang
MS
Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
Fu
Chang-Ling
CL
Olague-Marchan
Monica
M
Hacker
Mary K
MK
Zillikens
Detlef
D
Giudice
George J
GJ
Fairley
Janet A
JA
D015703:Antigens, CD / Q000378:metabolism; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D015820:Cadherins / Q000276:immunology; D016022:Case-Control Studies; D002455:Cell Division; D051183:Desmoglein 1; D051184:Desmoglein 3; D006801:Humans; D015151:Immunoblotting; D007070:Immunoglobulin A / Q000097:blood*; D009000:Monocytes / Q000276:immunology; D024041:Non-Fibrillar Collagens; D012872:Skin Diseases, Vesiculobullous / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D000097805:Collagen Type XVII
D015703:Antigens, CD; D001323:Autoantibodies; D001324:Autoantigens; D015820:Cadherins; D051183:Desmoglein 1; D051184:Desmoglein 3; D007070:Immunoglobulin A; D024041:Non-Fibrillar Collagens; D000097805:Collagen Type XVII; C071894:DSG3 protein, human